linjc16/ctgov huggingface dataset:
Study of Blood Samples From Patients With Ewing Sarcoma and Their Relatives

Study Overview
=================
Brief Summary
-----------------
RATIONALE: Studying samples of blood in the laboratory from patients with cancer and their relatives may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This research study is looking at blood samples collected from patients with Ewing sarcoma and their relatives.

Detailed Description
-----------------
OBJECTIVES: To identify and characterize a genetic susceptibility factor to Ewing's sarcoma by performing a Genome-Wide Association Study with as many as possible Ewing sarcoma patients. OUTLINE: This is a multicenter study. Blood samples are collected from patients and their relatives. Blood DNA samples are analyzed for susceptibility genes of Ewing Sarcoma.

Official Title
-----------------
GENEWING - A Genome Wide Association Study in Ewing Sarcoma

Conditions
-----------------
Sarcoma

Intervention / Treatment
-----------------
* Other: genome-wide association study


Participation Criteria
=================
Eligibility Criteria
-----------------
DISEASE CHARACTERISTICS: Patients with Ewing sarcoma Relatives of Ewing sarcoma patients PATIENT CHARACTERISTICS: Patients with a fusion genes specific of Ewing Sarcoma PRIOR CONCURRENT THERAPY: Not applicable

Ages Eligible for Study
-----------------
Minimum Age: 0 Years
Maximum Age: 120 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: genome-wide association study|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Identification and characterization of susceptibility genes in patients with Ewing sarcoma | Identification and characterization of susceptibility genes in patients with Ewing sarcoma | Through study completion, an average of 10 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Ewing sarcoma, Ewing sarcoma/peripheral primitive neuroectodermal tumor (PNET)
Long-term Control in Rhinosinusitis After Functional Endoscopic Sinus Surgery (FESS)

Study Overview
=================
Brief Summary
-----------------
State-of-the-art documents like ARIA and european position paper on rhinosinusitis (EPOS) provide clinicians with evidence-based treatment algorithms for allergic rhinitis (AR) and chronic rhinosinusitis (CRS) respectively (1)(2) . The currently available medications can alleviate symptoms associated with AR and RS, and most patients with RS benefit from endoscopic sinus surgery (ESS). In real life, a significant percentage of patients with AR and CRS continue to experience bothersome symptoms despite adequate treatment. This group with so-called severe chronic upper airway disease (SCUAD) represents a therapeutic challenge (3).

Official Title
-----------------
Long-term Control in Rhinosinusitis After FESS: Cross-sectional Observational Study on Control in Rhinosinusitis at a Mean Interval of 3 Years After FESS

Conditions
-----------------
Condition of Patient 3 Years After FESS-operation

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients that have undergone bilateral ESS for inflammatory sinonasal disease, without additional sino-nasal surgery after the ESS. Age > 18 and < 75 years. Written informed consent Dutch, French or English speaking patients Exclusion Criteria: Unilateral ESS Benign and malignant tumor disease Patient with a psychiatric, addictive, or any disorder of which the investigators feel at the time of evaluation for participation in the study that this may compromise the ability to give truly informed consent for participation in this study or provide reliable information on the questionnaire Lack of knowledge of Dutch, French or English

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 74 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| rhinosinusitis patients<br>patients having undergone endoscopic sinus surgery (ESS) for bilateral inflammatory sinonasal disease from January 2008 until December 2010. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Control Status of Patients With Rhinosinusitis | 1. Percentage of patients with rhinosinusitis that are fully controlled, partly controlled and uncontrolled according to the new european position paper on rhinosinusitis (EPOS) definitions at a mean interval of 3 years after endoscopic sinus surgery. | 3 years after FESS | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Control Nasal Endoscopy | Evaluating of difference in control if nasal endoscopy is performed three years after ESS. | 3 years after ESS |
Changes in Choroidal Thickness After Non Penetrating Deep Sclerectomy

Study Overview
=================
Brief Summary
-----------------
Prospective and observational study to determine if choroidal thickness increases after non penetrating deep sclerectomy in patients with open angle glaucoma

Official Title
-----------------
Changes in Choroidal Thickness After Non Penetrating Deep Sclerectomy

Conditions
-----------------
Choroidal Thickness, Open Angle Glaucoma, Non Penetrating Deep Sclerectomy

Intervention / Treatment
-----------------
* Procedure: Non penetrating deep sclerectomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Progressive Primary Open Angle Glaucoma Exclusion Criteria: Age under 18yrs Myopia or Hyperopia higher than -6D or +6D Secondary glaucoma Ocular surgery other than cataract Other ocular pathology
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Non penetrating deep sclerectomy|Non penetrating deep sclerectomy for open angle glaucoma|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in Choroidal thickness | Choroidal thickness measured by optic coherence tomography | before and 1 week, 1 month, 3 months and 6 months after non penetrating deep sclerectomy | 
| Change in Intraocular pressure | mmHg | before and 1 week, 1 month, 3 months and 6 months after non penetrating deep sclerectomy | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Choroidal thickness, Open Angle Glaucoma, Non penetrating deep sclerectomy
Continuous Azithromycin in Cystic Fibrosis Patients Beyond Two Years

Study Overview
=================
Brief Summary
-----------------
Azithromycin is an antibiotic currently prescribed continuously in cystic fibrosis patients. It was shown that this treatment taken every day or every week for 12 months, can improve the respiratory state of patients. From the second year of treatment, it would appear there is more profit to continue such treatment. The main objective is to study the association between continuous use of azithromycin and lung function measured by Forced expiratory volume in one second (FEV1), after two years of treatment.

Official Title
-----------------
Long Term Effects of Azithromycin in Patients With Cystic Fibrosis Using the National Database

Conditions
-----------------
Cystic Fibrosis

Intervention / Treatment
-----------------
* Drug: Azithromycin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with Cystic Fibrosis (whatever the genetic form) Age ≥ 8 years FEV ≥ 30% the year of azithromycin (N0) Continuous treatment with azithromycin for at least 2 years. Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 7 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Cystic fibrosis patients taking azithromycin<br>Cystic fibrosis patients taking azithromycin continuously for two years. | Drug: Azithromycin<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Forced expiratory volume in one second (FEV1). |  | yearly recorded, 2 years before initiation of Azithromycin and 4 years after initiation of Azithromycin | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Body Mass Index (BMI) |  | yearly recorded, 2 years before initiation of Azithromycin and 4 years after initiation of Azithromycin | 
| Number of IV antibiotics cures |  | yearly recorded, 2 years before initiation of Azithromycin and 4 years after initiation of Azithromycin | 
| Pseudomonas aeruginosa colonization |  | yearly recorded, 2 years before initiation of Azithromycin and 4 years after initiation of Azithromycin | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
azithromycin, cystic fibrosis, pulmonary function
Results of Shoulder Arthroscopic Surgery for Rotator Cuff, Biceps Tendon, Labrum and Capsule

Study Overview
=================
Brief Summary
-----------------
This study is a retrospective review of chart. Clinical results including range of motion, muscle power and scores will be recorded. Arthroscopic surgery of rotator cuff, labrum and capsule well be re-evaluated for clinical application.

Official Title
-----------------
Results of Shoulder Arthroscopic Surgery for Rotator Cuff, Biceps Tendon, Labrum and Capsule

Conditions
-----------------
Shoulder Arthroscopic Surgery

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Shoulder lesions including capsule, biceps, rotator cuff which indicated for arthroscopic surgery Exclusion Criteria: Open surgery for shoulder lesions Concomitant open and arthroscopic surgery

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Shoulder Arthroscopic Surgery
Evaluation of TTE Utilization in Medical Surgery Step-Down Unit

Study Overview
=================
Brief Summary
-----------------
This is a non-randomized, un-blinded study to evaluate Caption Health guidance software in patients in the medical surgery step-down unit. Patients will be scanned by a trained hospitalist and up to 4 standard views will be obtained per participant: PLAX, PSAX-PM, AP4 and SubC4. Observations will be made regarding human factors and performance of the device.

Official Title
-----------------
Evaluation of TTE Utilization in Medical Surgery Step-Down Unit: Use of AI Assisted Point-of-Care Echo With Guidance Technology

Conditions
-----------------
Cardiac Disease

Intervention / Treatment
-----------------
* Device: Caption Health Guidance Technology


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: . Patients ≥18 years old Patients in the medical surgery step-down clinical setting Patients who consent to participating in the study Exclusion Criteria: . ● Patients with emergent or urgent episodes of injury and illness that can lead to death or disability without rapid intervention Unable to lie flat for study Patients experiencing a known or suspected acute cardiac event at the time of evaluation Patients with severe chest wall abnormalities Patients who have undergone pneumonectomy Patients with recent abdominal surgery Patients unwilling or unable to give written informed consent Principal Investigator determination to exclude the subject from participation Investigators also have the right to withdraw patient from the study in the event of illness, adverse events, or other reasons concerning the health or well-being of the patient, or in the case of non-compliance.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 99 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: Caption Health Guidance Technology|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mean time to acquire images | Assess the time to acquire cardiac ultrasound images with and without Caption AI Gudiance | Up to 3 months | 
| Percentage of attempted studies with clinically useful images | Compare the percentage of clinically useful versus not useful images | Up to 3 Months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Artificial Intelligence, Cardiac Monitoring
Improving Trans-oral Surgical Outcomes Through Intra-operative Image Guidance

Study Overview
=================
Brief Summary
-----------------
The objective of this research is to perform a pilot study on patients undergoing laryngoscopy for diagnostic and tumor staging purposes (for pharyngeal or laryngeal cancer) in which intraoperative CT imaging will be performed both prior to (but after induction of general endotracheal anesthesia) and during placement of the laryngoscope in order to better understand anatomic changes that occur during instrumentation of the oral cavity and oropharynx. The goals of the study are: Develop a suite of de-identified images and surface renderings that qualitatively show how a tumor and the upper aerodigestive tract anatomy deform during a laryngoscopic evaluation. Create deformation models of the upper aerodigestive tract. This data to be used for future retractor development as well as for virtual image guided surgery.

Official Title
-----------------
Improving Trans-oral Surgical Outcomes Through Intra-operative Image Guidance

Conditions
-----------------
Oropharyngeal Cancer

Intervention / Treatment
-----------------
* Other: Intraoperative CT imaging


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patients (>18 years) seen in the Head and Neck Tumor Clinic who will require laryngoscopy in the operating room for diagnosis and staging of known or suspected tumors of the upper aerodigestive tract. Exclusion Criteria: Patients who are unable to tolerate general anesthesia. Patients who are felt to be a difficult airway for induction of general endotracheal anesthesia. Patients with excessive dental restorations and amalgam.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Intraoperative CT imaging<br> | Other: Intraoperative CT imaging<br>* Intraoperative CT scan of the upper aerodigestive tract during laryngoscopy procedure<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Radiographic evidence of upper aerodigestive tract deformation during laryngoscopy |  | Collected at the time of surgery |
Canadian Orthopaedic Foot and Ankle Society Surgical Treatment of Ankle Arthritis Outcome Study

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to see if the clinical outcome success rate of Total Ankle Arthroplasty is similar to that of Ankle Arthrodesis over a period of 10 years. This will include looking at whether Total ankle arthroplasty results in a lower rate of hindfoot arthrosis and arthritis after surgery compared to ankle joint arthrodesis and if the rate of complications and revision surgery is acceptable when compared to Ankle Arthrodesis over a period of 10 years.

Official Title
-----------------
Canadian Orthopaedic Foot and Ankle Society Surgical Treatment of Ankle Arthritis Outcome Study

Conditions
-----------------
Ankle Arthritis

Intervention / Treatment
-----------------
* Procedure: Ankle Arthroplasty
* Procedure: Ankle Arthrodesis


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Eighteen (18) or older Known to have ankle arthritis for more than six (6) months Tried non operative treatment measures (eg. activity modification, physiotherapy, orthotics, bracing etc.) and have not improved Patient tests (questionnaires) show that ankle arthritis is severe Patient willing to take part in the study, including signing consent form after carefully reading it Exclusion Criteria: Dead Bone in the Ankle Severe foot or Ankle Deformity Prior Ankle Fusion or Replacement Active or Prior Infection in the Ankle Obesity (greater than 250 lbs) Medical Conditions precluding safe surgery Nerve or Muscle disease Severe osteoporosis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Ankle Arthroplasty|nan|
|Procedure: Ankle Arthrodesis|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| AAOS Foot and Ankle Questionnaire - includes SF-36 |  | 10 years | 
| AOFAS Ankle-Hindfoot Scale |  | 10 years | 
| Ankle Osteoarthritis Scale |  | 10 years | 
| Foot Function Index |  | 10 years | 
| Radiographs |  | 10 years | 
| Complications |  | 10 years |
Immunogenicity and Safety Study of Pneumococcal 7-Valent Conjugate Vaccine in Sickle Cell Disease Infants.

Study Overview
=================
Brief Summary
-----------------
The primary objectives of this study were to assess the immunogenicity and the tolerance of the heptavalent pneumococcal conjugate vaccine (Prevenar) in young infants (2 months of age) with sickle cell disease when administred at 2,3, and 4 months of age.

Official Title
-----------------
An Open, Multicenter Clinical Trial to Investigate the Immunogenicity and Safety of the Pneumococcal 7-Valent Conjugate Vaccine (PREVENAR) in Sickle Cell Disease Infants.

Conditions
-----------------
Pneumococcal Infections

Intervention / Treatment
-----------------
* Biological: Pneumo 23


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria Infants with neonatal diagnosis of sickle cell disease and confirmed hemoglobin status by hemoglobin electrophoresis. Exclusion Criteria Previous immunization with pneumococcal-containing vaccines. History of pneumococcal invasive disease (meningitis, bacteremia, pneumonia). Known or suspected impairments of the immune system (including HIV infection) or recipients of immuno-suppressant agents. Other Exclusions apply.

Ages Eligible for Study
-----------------
Minimum Age: 57 Days
Maximum Age: 112 Days

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Biological: Pneumo 23|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Antibody responses to pneumococcal capsular polysaccharides antigens contained in PCV7 vaccine; local and systemic reactions. |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Opsonophagocytic activity; S. pneumoniae nasopharyngeal carriage. |  |  |
Safety and Efficacy of Recombinant Grass Pollen Allergen Cocktail in the Treatment of Allergic Rhinoconjunctivitis

Study Overview
=================
Brief Summary
-----------------
The trial is performed to assess efficacy and safety of a recombinant grass Pollen allergen cocktail in allergic rhinoconjunctivitis

Official Title
-----------------
A Multicentre Randomised Placebo-controlled Double-blind Clinical Trial for Evaluation of Safety and Efficacy of Immunotherapy With an Aluminium Hydroxide-adsorbed Cocktail of Recombinant Derivatives of Major Allergens of Timothy Grass (Phleum Pratense).

Conditions
-----------------
Allergy

Intervention / Treatment
-----------------
* Biological: Recombinant grass pollen


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Positive Skin Prick Test reaction to grass pollen Positive RAST result to grass pollen Positive Provocation Test result to grass pollen Exclusion Criteria: Serious chronic diseases Other relevant perennial allergies

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Biological: Recombinant grass pollen|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Allergy, Grass pollen, Recombinant